News

Researchers have identified promising new biologics with anti-tumor, insulin-sensitizing and hepatoprotective activities for obesity-related diseases.

An international team of scientists has developed an experimental direct-acting antiviral therapy to treat COVID-19. The antiviral approach used gene-silencing RNA technology known as siRNA (small-interfering RNA) to attack SARS-CoV-2's genome.

A four-month multi-drug therapy treated active tuberculosis as effectively as the standard six-month regimen, cutting treatment time by a third.

The addition of a third drug to a common dual-drug approach has been shown to reduce asthma exacerbations and improve control over the disease in those with moderate-to-severe asthma.

Using human pluripotent stem cells, scientists have created cardiac organoids – known as cardioids – that spontaneously organize themselves to develop a hollow chamber. Their research is published in the journal Cell.

An expert panel has provided guidance on best practices for the design of early drug trials for Alzheimer's disease, frontotemporal degeneration and other neurodegenerative dementias.

A new study suggests that while drugs with anticholinergic properties often play a key role in the treatment of schizophrenia, they may worsen brain functioning.

Researchers have shown that resistant triple-negative breast cancer cells are inhibited by 6-mercaptopurine and 5-azacitidine.

The early immune response in a person who has been vaccinated for COVID-19 can predict the level of protection they will have to the virus over time, according to analysis from Australian mathematicians, clinicians, and scientists.

A new cancer vaccine could enhance the positive effects of existing immunotherapies and boost the success rate of treatments from 20% to 75%, according to a new study published in Nature Communications.